RBC Capital Maintains Outperform on Elevance Health, Raises Price Target to $585
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Ben Hendrix maintains an Outperform rating on Elevance Health (NYSE:ELV) and raises the price target from $575 to $585.
July 18, 2024 | 2:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital analyst Ben Hendrix maintains an Outperform rating on Elevance Health and raises the price target from $575 to $585.
The raised price target and maintained Outperform rating from RBC Capital are positive signals for Elevance Health, likely boosting investor confidence and potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100